Abstract: AIM: To observe the therapeutically effect of diammonium glycyrrhizinate phosphatidylcholine complex (DGLL) on the non alcoholic fatty liver disease (NAFLD).METHODS: NAFLD rat model was constructed by feeding rats with high fatty and cholesterol diet for 8 weeks. And NAFLD model was subdivided into 6 subgroups: control group, model group, polygene phosphatidylcholine capsules group and DGLL groups (100,300,900 mg/kg). At the end of 12 week, all rats were killed to detect the blood lipids, oxidative stress, liver function, insulin-related and the pathological changes.RESULTS: DGLL could significantly reduce the NAFLD rats aminotransferase (ALT, AST) activity, malondialdehyde (MDA) content, TNF-α level, fasting blood glucose (FBG), fasting insulin (FINS) level and fasting insulin resistance index(HOMA-IR). DGLL could also increase superoxide dismutase (SOD) activity and improve NAFLD rats total cholesterol (TC) and triglyceride (TG) levels.CONCLUSION: DGLL can be used to treat NAFLD, and the mechanism may be related to lowering blood lipids and improving liver function, anti-oxidation and insulin resistance.

Key words: Non alcoholic fatty liver disease, Diammonium glycyrrhizinate phosphatidylcholine complex, Lipid peroxidation, Oxidative stress, Insulin resistance